We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys and Chimera Announce Cooperation and Co-Marketing Agreement
News

MorphoSys and Chimera Announce Cooperation and Co-Marketing Agreement

MorphoSys and Chimera Announce Cooperation and Co-Marketing Agreement
News

MorphoSys and Chimera Announce Cooperation and Co-Marketing Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys and Chimera Announce Cooperation and Co-Marketing Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Antibodies by Design, a Division of MorphoSys AG, Munich, and Chimera Biotec GmbH have announced the start of a co-marketing agreement between the two companies.

Within the scope of the agreement the parties agree to co-market generation of monoclonal antibodies by Antibodies by Design and Chimera Biotec’s complementary Imperacer ™assay technology for ultra-sensitive antigen detection.

Each partner will offer the services of the other to its customers throughout the world-wide market.

The Imperacer™ technology is designed to combine the advantages of protein detection through ELISA with the signal amplification typical for PCR. Imperacer™ uses antibody-DNA conjugates as a substitute for the antibody-enzyme conjugate used in ELISA.

Amplifying the conjugated marker-DNA typically results in a 100 - 10,000-fold increase in sensitivity over enzyme-linked assays.

Imperacer™ is currently used in human and veterinary diagnostics, bio-pharmaceutical research, biological defense, and in the food, beverage, and cosmetics industries.

It is used for a wide variety of sensitive analytic applications such as HIV and Hepatitis B detection, Prion analysis, pharmacokinetic studies, detection of toxins in food and beverages, and quality assurance for cosmetics.

Antibodies by Design uses HuCAL GOLD®, a proprietary recombinant antibody library technology to select antibodies against given antigen in record time. The process is performed entirely in vitro, and no laboratory animals are involved.

Pre-adsorption and intelligent counter-screening during the antibody generation process is used to drive the selection towards the epitopes on the antigen.

The process is designed to allow the selection and purification of specific antibodies in just 8 weeks. Rapid monoclonal antibody generation service using HuCAL GOLD® is offered worldwide to researchers both from academia and industry.

"We are very glad to gain access to Chimera Biotec’s innovative technology platform and to have the possibility to offer an additional highly sensitive antigen detection system to our customers," stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG.

"Since the availability of sufficient amounts of antigen material for reliable detection is sometimes a crucial problem for researchers, the combination of highly specific antibodies sourced from the MorphoSys HuCAL GOLD® antibody library with Chimera Biotec’s Imperacer™ approach could be a very attractive detection option."

"The high sensitivity of the Imperacer™ system demands highly specific antibodies to be effective, and many of our customers are seeking such antibodies for these assays," commented Jan Detmers, Business Development Manager of Chimera Biotec.

"We believe that the Antibodies by Design process is ideal for rapidly generating antibodies with the specificity our customers need in order for us to be able to develop the best assay."

Advertisement